Immunome, Inc. (NASDAQ:IMNM) Director Buys $57,470.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime acquired 7,000 shares of the stock in a transaction on Monday, March 24th. The stock was bought at an average price of $8.21 per share, with a total value of $57,470.00. Following the transaction, the director now directly owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. The trade was a 42.13 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Immunome Price Performance

Shares of Immunome stock opened at $7.09 on Thursday. Immunome, Inc. has a 1 year low of $6.94 and a 1 year high of $26.70. The company has a 50-day moving average of $9.61 and a 200 day moving average of $11.41. The firm has a market cap of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last announced its earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The business had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Guggenheim dropped their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Thursday, March 20th. Finally, Stephens restated an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $25.50.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after acquiring an additional 13,757 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Enavate Sciences GP LLC purchased a new stake in Immunome during the 4th quarter valued at about $36,939,000. Price T Rowe Associates Inc. MD increased its stake in Immunome by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,282,754 shares of the company’s stock valued at $24,243,000 after purchasing an additional 246,447 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Immunome by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 1,228,851 shares of the company’s stock worth $13,054,000 after buying an additional 21,396 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.